Sol Gel Technologies Ltd - Asset Resilience Ratio
Sol Gel Technologies Ltd (SLGL) has an Asset Resilience Ratio of 72.92% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2025)
This chart shows how Sol Gel Technologies Ltd's Asset Resilience Ratio has changed over time. Check strategic asset allocation of Sol Gel Technologies Ltd to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Sol Gel Technologies Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Sol Gel Technologies Ltd stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $42.69 Million | 72.92% |
| Total Liquid Assets | $42.69 Million | 72.92% |
Asset Resilience Insights
- Very High Liquidity: Sol Gel Technologies Ltd maintains exceptional liquid asset reserves at 72.92% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Sol Gel Technologies Ltd Industry Peers by Asset Resilience Ratio
Compare Sol Gel Technologies Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
ALTEOGEN Inc
KQ:196170 |
Biotechnology | 55.57% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 34.94% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Galapagos N.V.
AS:GLPG |
Biotechnology | 86.45% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
Annual Asset Resilience Ratio for Sol Gel Technologies Ltd (2017–2025)
The table below shows the annual Asset Resilience Ratio data for Sol Gel Technologies Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 43.34% | $12.97 Million | $29.92 Million | +30.96pp |
| 2024-12-31 | 12.38% | $4.44 Million | $35.85 Million | -54.93pp |
| 2023-12-31 | 67.31% | $30.48 Million | $45.29 Million | +21.89pp |
| 2022-12-31 | 45.42% | $21.18 Million | $46.63 Million | +11.95pp |
| 2021-12-31 | 33.47% | $23.16 Million | $69.19 Million | -39.30pp |
| 2020-12-31 | 72.77% | $43.05 Million | $59.16 Million | +5.94pp |
| 2019-12-31 | 66.83% | $40.97 Million | $61.30 Million | -15.92pp |
| 2018-12-31 | 82.75% | $57.66 Million | $69.68 Million | +56.63pp |
| 2017-12-31 | 26.12% | $4.00 Million | $15.31 Million | -- |
About Sol Gel Technologies Ltd
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treat… Read more